322 related articles for article (PubMed ID: 37522924)
1. The clinical application of atorvastatin in patients with small-cell lung cancer with dyslipidemia.
Kong F; Wang N; Gao F; Liang Y; Li L; Yu M; Zhao L; Zhang D; Jia Y
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13697-13704. PubMed ID: 37522924
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
Wang N; Zhao L; Zhang D; Kong F
Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
[TBL] [Abstract][Full Text] [Related]
3. Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study.
Kong F; Wang Z; Wang N; Zhang D; Liao D; Zhang J; Sun Y; Zhang H; Jia Y
Am J Cancer Res; 2023; 13(8):3679-3685. PubMed ID: 37693149
[TBL] [Abstract][Full Text] [Related]
4. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
6. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
8. Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy.
Zhu K; Jiang M; Xu Y; Chen P; Wang H; Yu J; Zhu J; Zhao W; Meng D; He Y
J Thorac Dis; 2021 Feb; 13(2):1205-1214. PubMed ID: 33717593
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer.
Xu Y; Wang X; Sun C; Gao Z; He H; Qiu S; Guo Y; Ma X; Song J; Ma K
Cancer Med; 2023 Feb; 12(3):2979-2989. PubMed ID: 36082491
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of durvalumab + chemotherapy
Zou Y; Ren X; Zhang H; Wang Y; Wang H; Bai R; Zhang Z; Sun G; Xu L
J Thorac Dis; 2023 Jun; 15(6):3339-3349. PubMed ID: 37426159
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.
Yuan J; Cheng F; Xiao G; Wang X; Fan H
Front Oncol; 2022; 12():917089. PubMed ID: 35795060
[TBL] [Abstract][Full Text] [Related]
12. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
13. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
16. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial.
Chen Y; Yu M; Liu Z; Zhang Y; Li Q; Yang G
Trials; 2021 Jul; 22(1):437. PubMed ID: 34238342
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
Wang L; Lei X; Wang X
Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
